| Id: | acc2491 |
| Group: | 2sens |
| Protein: | KLF4 |
| Gene Symbol: | KLF4 |
| Protein Id: | O43474 |
| Protein Name: | KLF4_HUMAN |
| PTM: | phosphorylation |
| Site: | Tyr20 |
| Site Sequence: | AVSDALLPSFSTFASGPAGRE |
| Disease Category: | Cancer |
| Disease: | Breast Cancer |
| Disease Subtype: | |
| Disease Cellline: | HTR |
| Disease Info: | |
| Drug: | tamoxifen |
| Drug Info: | "Tamoxifen is a selective estrogen receptor modulator (SERM) used primarily for the treatment of estrogen receptor-positive breast cancer in women, including adjuvant therapy, advanced cases, and recurrent disease, by competitively inhibiting estrogen binding to its receptor and suppressing cancer cell proliferation." |
| Effect: | resist |
| Effect Info: | Inhibiting Src or enhancing the ubiquitination of KLF4 by Dasatinib can restore the sensitivity of drug-resistant cells to tamoxifen. |
| Note: | |
| Score: | 5.0 |
| Pubmed(PMID): | 32084531 |
| Sentence Index: | 32084531_10-11 |
| Sentence: | We demonstrated phosphorylation of VHL by Src enhances proteolysis of VHL that in turn leads to upregulation of KLF4 and increases endocrine resistance. Suppression of Src-VHL-KLF4 cascade by Src inhibitor or enhancement of VHL-KLF4 ubiquitination by TAT-KLF4 (371-420AAa) peptides re-sensitizes tamoxifen-resistant breast cancer cells to tamoxifen treatment. |
Sequence & Structure:
MRQPPGESDMAVSDALLPSFSTFASGPAGREKTLRQAGAPNNRWREELSHMKRLPPVLPGRPYDLAAATVATDLESGGAGAACGGSNLAPLPRRETEEFNDLLDLDFILSNSLTHPPESVAATVSSSASASSSSSPSSSGPASAPSTCSFTYPIRAGNDPGVAPGGTGGGLLYGRESAPPPTAPFNLADINDVSPSGGFVAELLRPELDPVYIPPQQPQPPGGGLMGKFVLKASLSAPGSEYGSPSVISVSKGSPDGSHPVVVAPYNGGPPRTCPKIKQEAVSSCTHLGAGPPLSNGHRPAAHDFPLGRQLPSRTTPTLGLEEVLSSRDCHPALPLPPGFHPHPGPNYPSFLPDQMQPQVPPLHYQGQSRGFVARAGEPCVCWPHFGTHGMMLTPPSSPLELMPPGSCMPEEPKPKRGRRSWPRKRTATHTCDYAGCGKTYTKSSHLKAHLRTHTGEKPYHCDWDGCGWKFARSDELTRHYRKHTGHRPFQCQKCDRAFSRSDHLALHMKRHF
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| KLF4-Ser236 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.707 | ||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | 0.707 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| KLF4-Ser254 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.405 | ||||
| COAD | 0.945 | ||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | 0.043 | ||||
| LUAD | |||||
| LUSC | -1.393 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| KLF4-Thr316 | |
|---|---|
| Cancer | Intensity |
| BRCA | 1.625 |
| COAD | 0.003 |
| HGSC | |
| ccRCC | 0.808 |
| GBM | |
| HNSC | 0.961 |
| LUAD | 0.386 |
| LUSC | -1.144 |
| non_ccRCC | -0.919 |
| PDAC | -0.856 |
| UCEC | -0.864 |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| - | - | A | Lung cancer | Ubiquitination | 31748695 |
| - | - | D | Non-small cell lung cancer | Ubiquitination | 35098684 |
| K | 32 | P | Nasopharyngeal carcinoma | Ubiquitination | 31281496 |
| S | 234 | U | Nasopharyngeal carcinoma | Phosphorylation | 31281496 |
| - | - | U | Breast cancer | Ubiquitination | 31563563 |
| - | - | U | Hepatocellular carcinoma | Ubiquitination | 31730901 |
| - | - | U | Prostate cancer | Ubiquitination | 37301536 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
